The Medicines Gap: Why Children Are Still Waiting for Treatments Designed for Them

For millions of children, getting treatment is only part of the healthcare challenge. The medicines available must also be designed for their age, weight, developmental stage and specific medical needs. Yet across the global health system, developing treatments specifically for children remains an unfinished task, exposing a persistent gap between medical innovation and the realities of paediatric care.

The World Health Organization (WHO) is now calling for renewed global action to close this gap, warning that scientific advances alone will not guarantee that children receive safe, effective and appropriate medicines.

On World Children’s Day, November 20, the Global Accelerator for Paediatric Formulations Network (GAP-f), a WHO-hosted partnership, renewed its commitment to accelerating the development and availability of medicines designed specifically for children.

The initiative comes amid growing recognition that children cannot simply be treated as smaller versions of adults. Their bodies process medicines differently, and treatments developed primarily for adult patients may not always be available in formulations or doses appropriate for younger age groups.

This makes paediatric formulations an essential component of quality healthcare, rather than an optional addition to pharmaceutical development.

“Children should not have to wait for medicines that are designed for their needs,” said Dr Sylvie Briand, WHO Chief Scientist and Assistant Director General a.i. for Health Systems, Access and Data.

She emphasised the need to align global priorities, strengthen clinical research and help countries translate medical innovation into accessible treatments.

At the centre of this effort is GAP-f’s Strategic Roadmap 2025–2030, which establishes a shared framework for addressing gaps in paediatric medicine development and access.

Through its 30 by ’30 commitment, the network aims to assess priorities across 10 high-burden diseases, accelerate 10 priority medicines and strengthen paediatric medicines ecosystems in 10 countries by 2030.

The targets highlight an important shift in how global health partners are approaching children’s medicines: moving beyond developing treatments towards ensuring that research priorities, product development and national health systems work together to deliver them.

One of the major challenges is determining which medicines children need most.

Through WHO’s Paediatric Drug Optimization (PADO) process, GAP-f brings together experts and partners to identify priority medicines and formulations addressing critical gaps in the prevention and treatment of childhood diseases.

The process is intended to direct research and investment towards treatments where unmet needs are greatest, reducing fragmentation and encouraging collaboration among researchers, pharmaceutical developers and funders.

A dedicated GAP-f product portfolio will bring these priorities together, providing a common reference point for stakeholders working to develop medicines for children.

However, identifying priority treatments is only one part of the challenge. Medicines must also undergo appropriate clinical research to establish whether they are safe, effective and suitable for children.

GAP-f is therefore working with partners to strengthen paediatric clinical research, including mapping clinical research site capacity, promoting the inclusion of children in clinical studies and supporting more efficient research designs.

Its clinical research resources will bring together information on global paediatric clinical trial sites, study design and implementation learning materials, alongside recommendations to improve coordination among stakeholders.

This is particularly important because without sufficient evidence on how medicines work in children, health professionals and policymakers face limitations when determining the most appropriate treatments.

Yet even when suitable medicines are developed and evaluated, another challenge remains: ensuring they reach the children who need them.

Access is influenced by more than the availability of a pharmaceutical product. Countries also need functioning regulatory systems, procurement mechanisms, financing, distribution networks and health facilities capable of delivering appropriate treatments.

GAP-f is working with WHO technical departments, member states and partners to identify these barriers and support the uptake of age-appropriate medicines.

In May 2026, WHO and its partners convened a regional workshop on strengthening paediatric medicines ecosystems in Southeast Asia, bringing together stakeholders from four pilot countries.

The discussions focused on identifying challenges and practical solutions for strengthening national systems. A report from the workshop documents the findings and highlights opportunities for countries to translate global priorities into locally relevant interventions.

Although the workshop focused on Southeast Asia, its broader lesson is relevant to health systems across regions: developing a medicine does not automatically guarantee that it will reach a child in need.

For countries seeking to strengthen childhood healthcare, the challenge extends from pharmaceutical research laboratories to national health policies and the facilities where children receive treatment.

The GAP-f approach therefore places collaboration at the centre of closing the medicines gap.

Governments, researchers, pharmaceutical developers, regulators, funders and civil society all have a role in ensuring that scientific advances translate into accessible treatments.

As a WHO-hosted network, GAP-f provides a platform for aligning these different actors around shared priorities across the medicines development and delivery process.

Its 2030 ambitions will ultimately be measured not only by the number of medicines prioritised or research activities undertaken, but by whether children can access treatments that are safe, effective, affordable and appropriate for their needs.

The message on World Children’s Day is therefore a reminder that children’s healthcare must extend beyond making medicines available. It must also ensure that those medicines are developed with children in mind.

For a child waiting for treatment, progress in pharmaceutical research matters only when it reaches the health facility, the healthcare professional and, ultimately, the patient.

Closing the paediatric medicines gap will require more than scientific breakthroughs. It will demand sustained investment, stronger research partnerships and health systems capable of turning innovation into equitable access.

Every child deserves medicines designed for their needs, not solutions adapted as an afterthought.

Mercy Kachenge
Mercy Kachenge
Mercy Kachenge is a Kenyan multimedia journalist, communications professional and media consultant specializing in health, science, policy and development. She produces engaging, public-interest content across multiple media formats, translating complex issues, research and policy into clear and impactful stories.

Hot This Week

Zambia Receives Digital Farming Tools to Boost Smallholder Productivity

The Zambian Government has received digital agriculture technologies and...

AI, Digital Skills and Trust Take Centre Stage as Africa Tech Festival Closes

Artificial intelligence, digital skills, business accountability and access to...

EAC Calls for Better Water and Sanitation Data to Address Service Gaps

The East African Community (EAC) has urged Partner States...

Kenyan Pharmacist Wins Inaugural Africa Health Creator of the Year Award

Kenyan pharmacist and digital health advocate Dr Sonia Thuita...

The Hidden Health Cost of Following the Crowd

The loss of two children to measles left a...

Top Stories

Zambia Receives Digital Farming Tools to Boost Smallholder Productivity

The Zambian Government has received digital agriculture technologies and...

AI, Digital Skills and Trust Take Centre Stage as Africa Tech Festival Closes

Artificial intelligence, digital skills, business accountability and access to...

EAC Calls for Better Water and Sanitation Data to Address Service Gaps

The East African Community (EAC) has urged Partner States...

Kenyan Pharmacist Wins Inaugural Africa Health Creator of the Year Award

Kenyan pharmacist and digital health advocate Dr Sonia Thuita...

The Hidden Health Cost of Following the Crowd

The loss of two children to measles left a...

Emirates Opens Experiential Travel Store in Cape Town

Emirates has opened a new experiential Travel Store in...

TVS Motor Deepens African Ambitions Through New Mauritius Partnership

As competition intensifies in the global two-wheeler market, international...

Related Articles